Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
Rheumatol Ther. 2022 doi: 10.1007/s40744-022-00434-z
Merola and colleagues demonstrated a rapid and sustained reduction in hsCRP and the neutrophil-lymphocyte ratio (NLR) in patients with IMIDs with a high systemic inflammatory burden treated with secukinumab.
Numerous chronic inflammatory conditions are associate with cardiovascular disease. This includes psoriasis, psoriatic arthritis, and axial spondyloarthritis. In response to this, Merola, et al. investigated the effect of secukinumab, an IL-17A inhibitor, on cardiovascular risk in patients. This was a post hoc analysis of pooled data from Phase 3/4 secukinumab studies in psoriasis, PsA, and axSpA. Patients were excluded if they suffered from either uncontrolled hypertension or congestive heart failure. Traditional CV risk factors were also assessed.
This investigation also uncovered further benefits to the use of secukinumab in chronic inflammatory patients. In patients treated with secukinumab traditional CV risk factors – including BMI, fasting glucose, systolic and diastolic blood pressure – remained stable for at least 1 year.
Keywords:
